Behavioral Disorders Drug Development Pipeline Review, 2017 - Research and Markets

DUBLIN--(BUSINESS WIRE)--The "Behavioral Disorders Drug Development Pipeline Review, 2017" report has been added to Research and Markets' offering.

The report, "Behavioral Disorders Drug Development Pipeline Review, 2017" provides an overview of the behavioral disorders pipeline landscape.

The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for autism, obsessive-compulsive disorder and attention deficit hyperactivity disorder and features dormant and discontinued projects.

Scope

• Which companies are the most active within the pipeline for behavioral disorder therapeutics?
• Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
• To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
• What are the most important R&D milestones and data publications to have happened in the field of behavioral disorders?

Key Topics Covered:

1 Table of Contents

2 Introduction

3 Therapeutics Development

4 Therapeutics Assessment

5 Companies Involved in Therapeutics Development

6 Dormant Projects

7 Discontinued Products

8 Product Development Milestones

9 Appendix

Companies Mentioned

1. 4D Pharma PLC
2. 4P-Pharma SAS
3. APeT Holding BV
4. AbbVie Inc
5. Addex Therapeutics Ltd
6. Amarantus Bioscience Holdings Inc
7. Amorsa Therapeutics Inc
8. Anima Biotech Ltd
9. BCWorld Pharm Co Ltd
10. BioCrea GmbH
11. Curemark LLC
12. DRI Biosciences Corp
13. DURECT Corp
14. Eli Lilly and Company
15. F. Hoffmann-La Roche Ltd
16. GW Pharmaceuticals Plc
17. H. Lundbeck A/S
18. Heptares Therapeutics Ltd
19. Luc Therapeutics Inc
20. MedDay SA
21. Merck & Co Inc
22. Neos Therapeutics Inc
23. NeuroDerm Ltd
24. Novartis AG
25. Noven Pharmaceuticals Inc
26. Omeros Corp
27. OptiNose US Inc
28. Otsuka Pharmaceutical Co Ltd
29. Sumitomo Dainippon Pharma Co Ltd
30. Sunovion Pharmaceuticals Inc
31. Supernus Pharmaceuticals Inc
32. Taisho Pharmaceutical Holdings Co Ltd
33. Tris Pharma Inc

For more information about this report visit https://www.researchandmarkets.com/research/6srmq9/behavioral